Stock values continued to soar all last week for IntraBiotics Pharmaceuticals Inc. on two news items related to its lead product, iseganan hydrochloride, the latest of which outlined a special protocol assessment agreement with the FDA. (BioWorld Today)

Stock values continued to soar all last week for IntraBiotics Pharmaceuticals Inc. on two news items related to its lead product, iseganan hydrochloride, the latest of which outlined a special protocol assessment agreement with the FDA. (BioWorld Today)